



L&T INFOTECH

Soft growth; maintain BUY on strong TCV

- Q4 revenue growth of 3.6% QoQ CC below our estimate of 5%; however, net new TCV robust at US\$ 80mn, up 21% YoY
- EBIT margin largely in line at 17.3%, down 60bps QoQ due to rising employee cost
- We prune FY23/FY24 EPS by 4%/2% and roll over to a new TP of Rs 8,140 (vs. Rs 8,490). Retain BUY on strong guidance and robust TCV

Revenue miss: LTI's Q4FY22 revenue grew 3.6% QoQ CC vs. our estimate of 5%, after two consecutive quarters of 9%+ sequential growth. BFS/manufacturing saw muted growth of 2.8%/1.9% QoQ USD whereas the CPG, retail and pharma vertical performed well (+6.2%), followed by insurance (+3.9%) which recovered from a slump in Q3. Top-10 client growth was muted at 3.1% QoQ. However, on a full-year basis, LTI posted its highest-ever dollar revenue growth of 25.9% in FY22.

Margin in line: Q4 EBIT margin stood at 17.3% (17.9% est.), down 60bps QoQ due to increased employee cost. SG&A cost dipped 1.7% QoQ. Attrition surged to an alarming level of 24%, up 150bps QoQ and doubling YoY. LTI added 2,400 employees QoQ in Q4 and plans to roll out salary hikes from Apr'22. Amid rising employee cost due to the elevated attrition, management used the offshoring lever to the utmost – offshoring in Q4 reached a record high of 60.2% of quarterly revenue.

Deal wins robust: LTI's net new TCV rose 21% YoY to US\$ 80mn and constitutes four large deals, with a robust pipeline. Three deals are with Fortune 500 clients and one with a new account. Two wins were from BFS, with one each in the CPG and government healthcare verticals. Per management, the large-deal pipeline stands at ~US\$ 2bn and LTI is seeing broad-based demand across verticals and service lines.

FY23 outlook strong: LTI does not anticipate any slowdown in the demand environment but acknowledged uncertainty in terms of rising input costs and the volatile geopolitical climate. However, management expects to deliver leader quadrant growth in FY23 and PAT margin in the range of 14-15%.

Other takeaways: The board announced a dividend of Rs 30/sh (FY22 dividend at Rs 55/sh). DSO stood at 99 days in Q4 vs. 100 in Q3.

Maintain BUY: Factoring in the Q4 result, we cut FY23/FY24 EPS by 4%/2%. On rolling valuations over to Jun'24, our TP reduces to Rs 8,140 (from Rs 8,490) based on an unchanged 48.5x P/E. Maintain BUY on a robust demand environment.

Seema Nayak researchreport@bobcaps.in

20 April 2022

Technology & Internet

Key changes

	Target	Rating	
	•		
Ticke	er/Price	LTI IN/Rs 5,472	
Mark	et cap	US\$ 12.6bn	
Free	float	25%	
3M A	DV	US\$ 29.3mn	
52wk	high/low	Rs 7,589/Rs 3,525	
Prom	noter/FPI/DII	75%/8%/10%	

Source: NSE | Price as of 19 Apr 2022

Key financials

Y/E 31 Mar	FY21A	FY22A	FY23E
Total revenue (Rs mn)	123,698	156,687	185,784
EBITDA (Rs mn)	27,253	30,585	38,783
Adj. net profit (Rs mn)	19,383	22,986	27,454
Adj. EPS (Rs)	110.5	131.0	156.4
Consensus EPS (Rs)	110.5	125.4	145.8
Adj. ROAE (%)	30.5	28.5	28.6
Adj. P/E (x)	49.5	41.8	35.0
EV/EBITDA (x)	35.2	31.4	24.8
Adj. EPS growth (%)	27.8	18.6	19.4

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE





Fig 1 – Quarterly performance

(Rs mn)	Q4FY22	Q4FY21	YoY (%)	Q3FY22	QoQ (%)	FY22	FY21	YoY (%)
Revenues (US\$ mn)	570.4	447.4	27.5	553.0	3.1	2,103	1,670	25.9
Revenue	43,016	32,694	31.6	41,376	4.0	156,687	123,698	26.7
Operating Expenditure	34,552	25,539	35.3	33,065	4.5	126,102	96,445	30.8
Cost of revenues	30,111	22,233	35.4	28,547	5.5	108,567	82,193	32.1
as % of sales	70.0	68.0	-	69.0	-	277	266	-
SG&A expenses	4,441	3,306	34.3	4,518	(1.7)	17,535	14,252	23.0
as % of sales	10.3	10.1	-	10.9	-	45	46	-
EBITDA	8,464	7,155	18.3	8,311	1.8	30,585	27,253	12.2
Depreciation	1,019	826	23.4	885	15.1	3,549	3,325	6.7
EBIT	7,445	6,329	17.6	7,426	0.3	27,036	23,928	13.0
Other Income	1,151	839	-	811	-	3,939	1,955	-
PBT	8,596	7,168	19.9	8,237	4.4	30,975	25,883	19.7
Total Tax	2,221	1,711	29.8	2,112	5.2	7,989	6,500	22.9
Reported PAT	6,375	5,457	16.8	6,125	4.1	22,986	19,383	18.6
Reported EPS	36.3	31.1	16.8	34.9	4.1	131.0	110.5	18.6
Margins (%)			(bps)		(bps)			(bps)
EBITDA	19.7	21.9	(220)	20.1	(40)	19.5	22.0	(250)
EBIT	17.3	19.4	(210)	17.9	(60)	17.3	19.3	(210)
EBT	20.0	21.9	(190)	19.9	10	19.8	20.9	(120)
PAT	14.8	16.7	(190)	14.8	-	14.7	15.7	(100)
Effective Tax rate	25.8	23.9	200	25.6	20	25.8	25.1	70

Source: Company, BOBCAPS Research

Fig 2 – Operating metrics

	Q4FY22	Growth		
(in US\$ terms)	(% Contr. to Revenue)	QoQ (%)	YoY (%)	
Revenue by Vertical				
BFS	32.7	2.8	35.8	
Insurance	13.4	3.9	17.8	
Manufacturing	16.8	1.9	26.7	
Energy & Process	8.8	3.1	23.3	
CPG, Retail & Pharma	10.3	6.2	21.6	
High-Tech, Media & Entertainment	11.7	2.3	26.4	
Others	6.3	1.5	29.5	
Revenue by Geography				
North America	65.6	2.5	26.3	
Europe	16.2	5.8	25.2	
India	9.9	6.4	41.8	
RoW	8.3	-0.5	26.0	
Client Contribution to Revenue				
Top 5 clients	28.2	2.8	29.3	
Top 10 clients	40.4	3.1	25.6	
Top 20 clients	55.8	3.7	28.0	
Non top 20 client revenues	44.2	2.5	26.9	



	Q4FY22	Growth		
(in US\$ terms)	(% Contr. to Revenue)	QoQ (%)	YoY (%)	
Revenue by Service				
ADM and Testing	33.0	1.6	26.3	
Enterprise Solutions	30.8	1.2	21.6	
Infrastructure Management Services	13.7	7.1	15.7	
Analytics, AI & Cognitive	12.8	4.0	47.0	
Enterprise Integration & Mobility	9.7	7.6	50.8	

Source: Company, BOBCAPS Research



Valuation methodology

Factoring in the Q4FY22 result, we trim our FY23/FY24 EPS estimates by 4%/2%. On rolling valuations over to Jun'24, our TP reduces to Rs 8,140 (from Rs 8,490) based on an unchanged 48.5x P/E multiple. Maintain BUY on a robust demand environment and upbeat FY23 outlook.

Fig 3 – Revised estimates

(Po mn)		New			Old		(Change (%)	
(Rs mn)	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenues (US\$ mn)	2,103	2,477	2,816	2,081	2,462	2,823	1.1	0.6	(0.3)
YoY Growth (%)	25.9	17.8	13.7	24.6	18.3	14.7	-	-	-
Revenues	156,687	185,784	211,175	154,182	184,664	211,721	1.6	0.6	(0.3)
EBITDA	30,585	38,783	44,808	31,030	39,197	44,931	(1.4)	(1.1)	(0.3)
EBITDA margin (%)	19.5	20.9	21.2	20.1	21.2	21.2	-	-	-
Net profits	22,986	27,454	32,059	23,171	28,524	32,573	(0.8)	(3.8)	(1.6)
EPS (Rs)	131	156	183	132	163	186	(0.8)	(3.8)	(1.6)

Source: BOBCAPS Research

Key risks

Key downside risks to our estimates are:

- attrition impacting margins, and
- slowdown in European demand.

Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
Coforge	COFORGE IN	3.3	4,027	7,080	BUY
eClerx Services	ECLX IN	1.2	2,426	3,790	BUY
HCL Technologies	HCLT IN	38.0	1,070	1,610	BUY
Infosys	INFO IN	86.9	1,562	2,130	BUY
L&T Infotech	LTI IN	12.6	5,472	8,140	BUY
Mindtree	MTCL IN	7.8	3,636	5,610	BUY
Mphasis	MPHL IN	7.0	2,857	3,470	HOLD
Persistent Systems	PSYS IN	4.4	4,174	4,580	HOLD
Tata Consultancy Services	TCS IN	170.3	3,472	4,660	BUY
Tech Mahindra	TECHM IN	14.8	1,301	1,940	BUY
Wipro	WPRO IN	38.3	530	850	BUY

Source: BOBCAPS Research, NSE | Price as of 19 Apr 2022



Financials

Y/E 31 Mar (Rs mn)	FY20A	FY21A	FY22A	FY23E	FY24E
Total revenue	108,786	123,698	156,687	185,784	211,175
EBITDA	20,291	27,253	30,585	38,783	44,808
Depreciation	2,731	3,325	3,549	4,273	4,857
EBIT	17,560	23,928	27,036	34,510	39,951
Net interest inc./(exp.)	0	0	0	0	0
Other inc./(exp.)	2,463	1,955	3,939	2,341	3,081
Exceptional items	0	0	0	0	0
EBT	20,023	25,883	30,975	36,851	43,032
Income taxes	4,825	6,500	7,989	9,397	10,973
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	0	0	0	0	0
Reported net profit	15,198	19,383	22,986	27,454	32,059
Adjustments	0	0	0	0	0
Adjusted net profit	15,198	19,383	22,986	27,454	32,059

Balance Sheet					
Y/E 31 Mar (Rs mn)	FY20A	FY21A	FY22A	FY23E	FY24E
Accounts payables	0	0	0	0	0
Other current liabilities	23,618	23,175	25,317	30,018	34,121
Provisions	2,908	3,956	4,393	5,209	5,921
Debt funds	7,571	6,854	6,675	6,675	6,675
Other liabilities	101	35	105	105	105
Equity capital	174	175	175	175	175
Reserves & surplus	53,877	72,896	88,028	103,913	122,462
Shareholders' fund	54,051	73,071	88,203	104,088	122,637
Total liab. and equities	88,249	107,091	124,693	146,095	169,459
Cash and cash eq.	5,252	7,594	3,949	22,330	35,520
Accounts receivables	27,541	26,906	37,368	45,810	52,070
Inventories	0	0	0	0	0
Other current assets	10,442	15,111	24,536	17,815	20,250
Investments	22,186	36,282	31,366	31,366	31,366
Net fixed assets	19,788	19,722	25,790	27,090	28,569
CWIP	0	0	0	0	0
Intangible assets	1,316	2,667	3,157	3,157	3,157
Deferred tax assets, net	3,039	1,476	1,684	1,684	1,684
Other assets	0	0	0	0	0
Total assets	88,248	107,091	124,693	146,095	169,459

Cash Flows

Y/E 31 Mar (Rs mn)	FY20A	FY21A	FY22A	FY23E	FY24E
Cash flow from operations	16,273	17,700	16,480	33,805	30,214
Capital expenditures	(5,480)	(3,379)	(8,556)	(5,574)	(6,335)
Change in investments	0	(5,390)	(559)	0	0
Other investing cash flows	(3,287)	1,862	(552)	1,718	2,821
Cash flow from investing	(8,767)	(6,907)	(9,667)	(3,855)	(3,514)
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	0	0	(1,661)	0	0
Interest expenses	0	0	(48)	0	0
Dividends paid	(6,404)	(8,451)	(8,749)	(11,569)	(13,510)
Other financing cash flows	0	0	0	0	0
Cash flow from financing	(6,404)	(8,451)	(10,458)	(11,569)	(13,510)
Chg in cash & cash eq.	1,102	2,342	(3,645)	18,381	13,190
Closing cash & cash eq.	5,252	7,594	3,949	22,330	35,520

Per Share					
Y/E 31 Mar (Rs)	FY20A	FY21A	FY22A	FY23E	FY24
Reported EPS	86.4	110.5	131.0	156.4	182.
Adjusted EPS	86.4	110.5	131.0	156.4	182.
Dividend per share	30.2	40.0	45.8	54.8	63.
Book value per share	307.3	416.4	502.6	593.1	698.
Valuations Ratios					
Y/E 31 Mar (x)	FY20A	FY21A	FY22A	FY23E	FY24
EV/Sales	8.8	7.8	6.1	5.2	4.
EV/EBITDA	47.1	35.2	31.4	24.8	21.
Adjusted P/E	63.3	49.5	41.8	35.0	30.
P/BV	17.8	13.1	10.9	9.2	7.
DuPont Analysis					
Y/E 31 Mar (%)	FY20A	FY21A	FY22A	FY23E	FY24
Tax burden (Net profit/PBT)	75.9	74.9	74.2	74.5	74.
Interest burden (PBT/EBIT)	114.0	108.2	114.6	106.8	107.
EBIT margin (EBIT/Revenue)	16.1	19.3	17.3	18.6	18.
Asset turnover (Rev./Avg TA)	140.4	126.6	135.2	137.2	133.
Leverage (Avg TA/Avg Equity)	1.5	1.5	1.4	1.4	1.
Adjusted ROAE	29.5	30.5	28.5	28.6	28.
Ratio Analysis Y/E 31 Mar	FY20A	FY21A	FY22A	FY23E	FY24
YoY growth (%)	-			-	
Revenue	15.2	13.7	26.7	18.6	
		13.1			13.
EBITDA	7.7	34.3	12.2	26.8	
					15.
Adjusted EPS	7.7	34.3	12.2	26.8	15.
Adjusted EPS Profitability & Return ratios (%)	7.7	34.3	12.2	26.8	15. 16.
Adjusted EPS Profitability & Return ratios (%) EBITDA margin	7.7 0.0	34.3 27.8	12.2 18.6	26.8 19.4	15. 16. 21.
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin	7.7 0.0 18.7	34.3 27.8 22.0	12.2 18.6 19.5	26.8 19.4 20.9	15. 16. 21. 18.
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin	7.7 0.0 18.7 16.1 14.0	34.3 27.8 22.0 19.3 15.7	12.2 18.6 19.5 17.3 14.7	26.8 19.4 20.9 18.6 14.8	15. 16. 21. 18. 15.
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE	7.7 0.0 18.7 16.1	34.3 27.8 22.0 19.3	12.2 18.6 19.5 17.3	26.8 19.4 20.9 18.6	15. 16. 21. 18. 15. 28.
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE	7.7 0.0 18.7 16.1 14.0 29.5	34.3 27.8 22.0 19.3 15.7 30.5	12.2 18.6 19.5 17.3 14.7 28.5	26.8 19.4 20.9 18.6 14.8 28.6	15. 16. 21. 18. 15. 28.
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE	7.7 0.0 18.7 16.1 14.0 29.5	34.3 27.8 22.0 19.3 15.7 30.5	12.2 18.6 19.5 17.3 14.7 28.5	26.8 19.4 20.9 18.6 14.8 28.6	15. 16. 21. 18. 15. 28. 43.
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days) Receivables	7.7 0.0 18.7 16.1 14.0 29.5 34.7	34.3 27.8 22.0 19.3 15.7 30.5 37.1	12.2 18.6 19.5 17.3 14.7 28.5 33.1	26.8 19.4 20.9 18.6 14.8 28.6 38.4	15. 16. 21. 18. 15. 28. 43. 8
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days) Receivables Inventory	7.7 0.0 18.7 16.1 14.0 29.5 34.7 86	34.3 27.8 22.0 19.3 15.7 30.5 37.1 80	12.2 18.6 19.5 17.3 14.7 28.5 33.1 75	26.8 19.4 20.9 18.6 14.8 28.6 38.4 82	15. 16. 21. 18. 15. 28. 43. 8
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days) Receivables Inventory Payables	7.7 0.0 18.7 16.1 14.0 29.5 34.7 86 0	34.3 27.8 22.0 19.3 15.7 30.5 37.1 80 0	12.2 18.6 19.5 17.3 14.7 28.5 33.1 75 0	26.8 19.4 20.9 18.6 14.8 28.6 38.4 82 0	15. 16. 21. 18. 15. 28. 43. 8
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days) Receivables Inventory Payables Ratios (x)	7.7 0.0 18.7 16.1 14.0 29.5 34.7 86 0	34.3 27.8 22.0 19.3 15.7 30.5 37.1 80 0	12.2 18.6 19.5 17.3 14.7 28.5 33.1 75 0	26.8 19.4 20.9 18.6 14.8 28.6 38.4 82 0	15. 16. 21. 18. 15. 28. 43. 8 8
EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days) Receivables Inventory Payables Ratios (x) Gross asset turnover Current ratio	7.7 0.0 18.7 16.1 14.0 29.5 34.7 86 0 11	34.3 27.8 22.0 19.3 15.7 30.5 37.1 80 0 13	12.2 18.6 19.5 17.3 14.7 28.5 33.1 75 0 12	26.8 19.4 20.9 18.6 14.8 28.6 38.4 82 0 12	15. 16. 21. 18. 15. 28. 43. 8 43. 1 7.
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days) Receivables Inventory Payables Ratios (x) Gross asset turnover	7.7 0.0 18.7 16.1 14.0 29.5 34.7 86 0 11 11	34.3 27.8 22.0 19.3 15.7 30.5 37.1 80 0 13 6.3	12.2 18.6 19.5 17.3 14.7 28.5 33.1 75 0 12 6.9	26.8 19.4 20.9 18.6 14.8 28.6 38.4 82 0 12 7.0	13. 15. 16. 21. 18. 15. 28. 43. 43. 7. 7. 2. N.

Adjusted debt/equity Source: Company, BOBCAPS Research | Note: TA = Total Assets



Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months


BUY - Expected return >+15%


HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.





B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

Rating distribution

As of 31 March 2022, out of 116 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 65 have BUY ratings, 31 have HOLD ratings, 5 are rated ADD*, 1 is rated REDUCE* and 14 are rated SELL. One company rated ADD has been an investment banking client in the last 12 months. (*Our ADD and REDUCE ratings are in the process of being migrated to the new recommendation structure.)

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017. BOBCAPS CIN Number: U65999MH1996GOI098009.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

L&T INFOTECH



This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.